Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker reported strong operating results for the first quarter of 2024, with a 9.7% increase in net sales to $5.2 billion, 10% organic net sales growth, and a 33.1% increase in reported EPS. The company's MedSurg and Neurotechnology segment saw a 11.5% increase in net sales, while Orthopaedics and Spine segment reported a 7.5% increase. Adjusted operating income margin increased to 21.9%, and adjusted EPS rose by 16.8%. Stryker expects full year 2024 organic net sales growth in the range of 8.5% to 9.5%, with adjusted net earnings per diluted share projected to be between $11.85 to $12.05.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.